Take orally once daily in the evening, with or without food. For exercise-induced bronchoconstriction, take at least 2 hours before exercise.

Montelukast selectively blocks the cysteinyl leukotriene type 1 (CysLT1) receptors in the airways. Leukotrienes are potent inflammatory mediators released from various cells, including mast cells and eosinophils, and cause bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment, which are involved in asthma and allergic rhinitis pathogenesis. By blocking these receptors, Montelukast reduces bronchoconstriction and inflammatory responses.

• •Hypersensitivity to montelukast or any component of the formulation.
• •Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

In cases of overdose, the most frequently occurring adverse events were abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. No specific antidote is known. Treatment is symptomatic and supportive.

Pregnancy Category B. Use during pregnancy only if clearly needed. Montelukast is excreted in breast milk; caution should be exercised when administered to a nursing woman. Consult a doctor.